Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units

Autor: S. G. Hilsenbeck, Mace L. Rothenberg, Von Hoff Dd, Shimada Y, Burris Ha rd, Degen D

Publikováno v: Anti-Cancer Drugs. 5:202-206

CPT-11 (irinotecan hydrochloride, 7-ethyl-10-[4-(piperidino)-1-piperidino] carbonyloxy-camptothecin) is a semisynthetic camptothecin derivative developed in Japan. The inhibitory activity of CPT-11 against human tumor colony-forming units from freshl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d86f99de273a7144e5a7ce6a58e383a9
https://doi.org/10.1097/00001813-199404000-00011

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Autor: Reid T; Moores Cancer Center, University of California and San Diego, La Jolla, CA, USA. Electronic address: tonyreid@ucsd.edu., Oronsky B; EpicentRx, Mountain View, CA, USA., Scicinski J; EpicentRx, Mountain View, CA, USA., Scribner CL; RRD International, Rockville, MD, USA., Knox SJ; Department of Radiation Oncology, Stanford University, Stanford, CA, USA., Ning S; Department of Radiation Oncology, Stanford University, Stanford, CA, USA., Peehl DM; Department of Urology, Stanford University, Stanford, CA, USA., Korn R; Imaging Endpoints, Scottsdale, AZ, USA., Stirn M; EpicentRx, Mountain View, CA, USA., Carter CA; Walter Reed National Military Medical Center, Bethesda, MD, USA., Oronsky A; InterWest Partners, Menlo Park, CA, USA., Taylor MJ; NonClinical Safety Assessment, Mountain View, CA, USA., Fitch WL; Stanford University School of Medicine, Stanford, CA, USA., Cabrales P; Department of Bioengineering, University of California and San Diego, La Jolla, CA, USA., Kim MM; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA., Burris HA Rd; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA., Lao CD; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA., Abrouk NED; Innovexe, Mountain View, CA, USA., Fanger GR; EpicentRx, Mountain View, CA, USA., Infante JR; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2015 Sep; Vol. 16 (9), pp. 1133-1142. Date of Electronic Publication: 2015 Aug 19.